Development leader with deep cell therapy expertise joins as Aspect advances its programs towards clinical development
Vancouver, BC, Canada – April 29, 2026 – Aspect Biosystems, a biotechnology company pioneering the development of a novel category of cellular medicines, today announced the appointment of Mike Scott as Chief Development Officer. Mike will lead Aspect’s development efforts, including early clinical development execution and regulatory strategy.
“At Aspect, we are developing curative cellular medicines for some of the most elusive diseases,” said Tamer Mohamed, Chief Executive Officer, Aspect Biosystems. “We combine our powerful technology, vertically integrated capabilities, and world-class team with deep expertise across science, engineering, and cell therapy development to deliver on our mission and build a category-defining company. Mike’s appointment builds on a series of recent leadership additions that have bolstered our development expertise. He brings exceptional experience in cell therapy development and he will play a key role as we advance our therapeutic pipeline and drive patient impact.”
Mike brings strong expertise in advancing complex cell therapy and combination products through early clinical development. Prior to joining Aspect, Mike was Vice President of Cell Therapy Medical Devices at Novo Nordisk where he led the development of device and combination products for type 1 diabetes, chronic heart failure, and Parkinson’s disease. Mike has a strong clinical development track record, having advanced multiple programs through first-in-human studies while in his previous roles as Senior Vice President of Product Development at BlueRock Therapeutics (acquired by Bayer) and Chief Development Officer at ViaCyte (acquired by Vertex Pharmaceuticals). He holds a PhD in Medical Biophysics from Western University.
“Having known Aspect’s leadership for several years, I have been impressed with the company’s deep expertise, strong culture, and focus on rapidly advancing therapies into the clinic,” said Mike Scott, Chief Development Officer, Aspect Biosystems. “With industry-leading capabilities across pluripotent stem cells, immune evasion through its bioprinting and hypoimmune cell engineering platforms, and clinical manufacturing, Aspect is uniquely positioned to advance its programs toward clinical development and deliver meaningful patient outcomes. I couldn’t be more excited to join this team as we work to transform how serious diseases are treated and deliver curative medicines.”
About Aspect Biosystems
Aspect Biosystems is a biotechnology company pioneering the development of a novel category of cellular medicines designed to replace or restore biological function and deliver curative therapies for some of the most serious diseases. Aspect is developing these bioengineered cellular medicines by applying its full-stack platform, which integrates proprietary AI-powered bioprinting technology, stem cells, hypoimmune cell engineering, and advanced biomaterials. Aspect is advancing its therapeutic pipeline across multiple endocrine and metabolic diseases, including diabetes and rare endocrine disorders. Learn more at www.aspectbiosystems.com.
Contact
Natalie Korenic
Aspect Biosystems
media@aspectbiosystems.com